These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 28577949)

  • 21. Possible differential EGFR-TKI efficacy among exon 19 deletional locations in EGFR-mutant non-small cell lung cancer.
    Kaneda T; Hata A; Tomioka H; Tanaka K; Kaji R; Fujita S; Tomii K; Katakami N
    Lung Cancer; 2014 Nov; 86(2):213-8. PubMed ID: 25304185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Correlation Analysis of Ki67 Expression and EGFR Mutation on the Risk of Recurrence and Metastasis in Postoperative Patients with Stage I Lung Adenocarcinoma].
    Xu L; Guo R
    Zhongguo Fei Ai Za Zhi; 2022 Dec; 25(12):852-861. PubMed ID: 36617471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic implication of EGFR gene mutations and histological classification in patients with resected stage I lung adenocarcinoma.
    Lin CY; Wu YM; Hsieh MH; Wang CW; Wu CY; Chen YJ; Fang YF
    PLoS One; 2017; 12(10):e0186567. PubMed ID: 29065153
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes.
    Lee HJ; Kim YT; Kang CH; Zhao B; Tan Y; Schwartz LH; Persigehl T; Jeon YK; Chung DH
    Radiology; 2013 Jul; 268(1):254-64. PubMed ID: 23468578
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Relevance of EGFR mutation with micropapillary pattern according to the novel IASLC/ATS/ERS lung adenocarcinoma classification and correlation with prognosis in Chinese patients.
    Chao L; Yi-Sheng H; Yu C; Li-Xu Y; Xin-Lan L; Dong-Lan L; Jie C; Yi-Lon W; Hui LY
    Lung Cancer; 2014 Nov; 86(2):164-9. PubMed ID: 25236981
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma.
    Kim MH; Shim HS; Kang DR; Jung JY; Lee CY; Kim DJ; Lee JG; Bae MK; Kim HR; Lim SM; Kim EY; Park JS; Chung KY; Kim HJ; Kim JH; Cho BC
    Lung Cancer; 2014 Mar; 83(3):389-95. PubMed ID: 24462463
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.
    Sun PL; Seol H; Lee HJ; Yoo SB; Kim H; Xu X; Jheon S; Lee CT; Lee JS; Chung JH
    J Thorac Oncol; 2012 Feb; 7(2):323-30. PubMed ID: 22237264
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
    Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
    J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Matched-pair analysis of a multi-institutional cohort reveals that epidermal growth factor receptor mutation is not a risk factor for postoperative recurrence of lung adenocarcinoma.
    Matsumura Y; Suzuki H; Ohira T; Shiono S; Abe J; Sagawa M; Sakurada A; Katahira M; Machida Y; Takahashi S; Okada Y
    Lung Cancer; 2017 Dec; 114():23-30. PubMed ID: 29173761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy.
    Li R; Li Q; Lin S; Li W; Yu L; Wang L; Dong X; Yu L; Li S; Liu W; Li B
    Clin Transl Oncol; 2019 Mar; 21(3):298-303. PubMed ID: 30022385
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association between tumor epidermal growth factor receptor mutation and pulmonary tuberculosis in patients with adenocarcinoma of the lungs.
    Luo YH; Wu CH; Wu WS; Huang CY; Su WJ; Tsai CM; Lee YC; Perng RP; Chen YM
    J Thorac Oncol; 2012 Feb; 7(2):299-305. PubMed ID: 22173705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological characteristics of EGFR mutated adenosquamous carcinoma of the lung.
    Shiozawa T; Ishii G; Goto K; Nagai K; Mimaki S; Ono S; Niho S; Fujii S; Ohe Y; Tsuchihara K; Ochiai A
    Pathol Int; 2013 Feb; 63(2):77-84. PubMed ID: 23464964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
    Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
    Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
    [TBL] [Abstract][Full Text] [Related]  

  • 36. RhoB determines tumor aggressiveness in a murine EGFRL858R-induced adenocarcinoma model and is a potential prognostic biomarker for Lepidic lung cancer.
    Calvayrac O; Pradines A; Raymond-Letron I; Rouquette I; Bousquet E; Lauwers-Cances V; Filleron T; Cadranel J; Beau-Faller M; Casanova A; Milia J; Favre G; Mazières J
    Clin Cancer Res; 2014 Dec; 20(24):6541-50. PubMed ID: 25320360
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA.
    Nakamura T; Sueoka-Aragane N; Iwanaga K; Sato A; Komiya K; Kobayashi N; Hayashi S; Hosomi T; Hirai M; Sueoka E; Kimura S
    J Thorac Oncol; 2012 Sep; 7(9):1369-81. PubMed ID: 22858585
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Epidermal Growth Factor Receptor Mutation Status and Treatment Outcome for R0-Resected Patients with Stage 3 Non-small Cell Lung Cancer.
    Liu SR; Qiu B; Yang H; Liang Y; Wang F; Liu SL; Chen ZL; Zhang L; Liu MZ; Wang SY; Lin LF; Liu H
    Ann Surg Oncol; 2016 Jun; 23(6):2115-22. PubMed ID: 26887852
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Epidermal Growth Factor Receptor Mutation as a Risk Factor for Recurrence in Lung Adenocarcinoma.
    Hayasaka K; Shiono S; Matsumura Y; Yanagawa N; Suzuki H; Abe J; Sagawa M; Sakurada A; Katahira M; Takahashi S; Endoh M; Okada Y
    Ann Thorac Surg; 2018 Jun; 105(6):1648-1654. PubMed ID: 29486179
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic value of epidermal growth factor receptor mutations and histologic subtypes with lung adenocarcinoma.
    Motono N; Funasaki A; Sekimura A; Usuda K; Uramoto H
    Med Oncol; 2018 Jan; 35(3):22. PubMed ID: 29387978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.